November 10, 2020

Mr. Anil Patni, Lead for Capacity Planning at Dr. Reddy's Laboratories participated and presented in the Manufacturing Chemist Live 2020 Virtual event organized by HPCi Media Limited on November 10, 2020.

Mr. Patn…

November 3, 2020

We’re delighted to announce that our API team has been recognized as the ‘API Supplier of the Year’ at the Global Generics & Biosimilars Awards 2020 – for the second consecutive year! We received the award for moving q…

October 19, 2020

We are honored that our sustainability initiative has been recognized with the CPhI Pharma Award 2020 in the category of ‘Excellence in Pharma: Sustainability’.

The Judging Panel, which is comprised of independent,…

October 5, 2020

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third Asian pharmaceutical company…

October 5, 2020

Session Recording

October 13, 2020

Session Recording

July 01, 2020

Hyderabad, India, July 01, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, hereafter referred to as “Dr. Reddy’s”) announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co.…

Certificate of Suitability (CEP) for the API Levofloxacin Hemihydrate has been granted.

Dr. Reddy’s is among the first companies to receive the CEP from the European Directorate for the Quality of Medicines (EDQM). Together with our expand…

Dr. Reddy’s has filed the US DMF for Apalutamide, which expands our oncology API portfolio further and demonstrates our strength in R&D and regulatory affairs.

Our API partners now have access to the US DMF and validated batch samples.…